Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.47 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anisole SCHEMBL27710875 | 0.87 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP17A1CYP2C19CYP1A2 | |
| SCHEMBL6114529 | 0.84 | CYP11B1 (0.45) | CYP11B1CYP11B2PRKCZADRA2AADRA2B | |
| SCHEMBL19383227 | 0.82 | PDE10A (0.48) | CYP11B1CYP11B2ATMCYP1A2PDE10A | |
| SCHEMBL12854176 | 0.82 | CYP11B1 (0.44) | CYP11B1CYP11B2PRKCZPDE5APDE3B | |
| SCHEMBL6114713 | 0.81 | TLR8 (0.45) | CYP11B1CYP11B2PRKCZADORA1ALDH1A1 | |
| SCHEMBL2258454 | 0.81 | CYP11B1 (0.49) | CYP11B1CYP11B2PRKCZADRA2AADRA2B | |
| SCHEMBL12853967 | 0.80 | CYP11B1 (0.42) | CYP11B1CYP11B2PRKCZADRA2AADRA2B | |
| SCHEMBL6114616 | 0.80 | TLR8 (0.46) | CYP11B1CYP11B2ATMALDH1A1HSD17B10 | |
| SCHEMBL12854049 | 0.80 | CYP1A2 (0.47) | CYP11B1CYP11B2PRKCZADRA2AADRA2B | |
| SCHEMBL1272086 | 0.80 | CYP11B1 (0.42) | CYP11B1CYP11B2PRKCZADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796800-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2017-10-24 | — | — | US | claimed |
| US-20160108153-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2016-04-21 | — | — | US | claimed |
| US-9249244-B2 | Process for producing polydienes | BRIDGESTONE CORPORATION (JP) | 2016-02-02 | — | — | US | claimed |
| EP-2619233-A1 | PROCESS FOR PRODUCING POLYDIENES | Bridgestone Corporation (JP) | 2013-07-31 | — | — | EP | claimed |
| WO-2012040026-A1 | PROCESS FOR PRODUCING POLYDIENES | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | WO | claimed |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| EP-3641776-B1 | ATROPISOMERISM FOR ENHANCED KINASE INHIBITOR SELECTIVITY | SAN DIEGO STATE UNIV RESEARCH FOUNDATION (US) | 2023-10-18 | — | — | EP | disclosed |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-4245743-A1 | METHOD FOR PREPARATION OF DEUTERATED ANTHRACENE COMPOUND, REACTION COMPOSITION, DEUTERATED ANTHRACENE COMPOUND, AND COMPOSITION | Lg Chem, Ltd. (KR) | 2023-09-20 | — | — | EP | disclosed |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | 280 Bio, Inc (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-06-22 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7449479-B2 | Serine protease inhibition via 1-{[1-(2-Methoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | TORRENT PHARMACEUTICALS LTD. (IN) | 2008-08-28 | — | — | US | disclosed |
| US-20080176815-A1 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2008-07-24 | — | — | US | disclosed |
| US-7378422-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-05-27 | — | — | US | disclosed |
| US-7291623-B2 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2007-11-06 | — | — | US | disclosed |
| US-4396619-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1983-08-02 | — | — | US | disclosed |
| US-4382932-A | Isoquinolinium substituted cephalosporins | ELI LILLY AND COMPANY (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176815-A1 | Compounds that interact with kinases | MAP3K6, MAP3K20, MAP4K2 | CYP11B1 1304/4885CYP11B2 1420/4885PRKCZ 198/4885 |
| US-20230242552-A1 | Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof | NRAS, KRAS, RAB8A | CYP11B1 16/4885CYP11B2 17/4885PRKCZ 3261/4885 |
| US-20230192663-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | CYP11B1 2499/4885CYP11B2 2044/4885PRKCZ 1929/4885 |
| US-20240228512-A1 | ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | AZI2, HDAC5, HDAC4 | CYP11B1 1136/4885CYP11B2 744/4885PRKCZ 1331/4885 |
| US-20230312565-A1 | 1H-PYRROLO[3,2-C]PYRIDINE AND 1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS | TLR9, TLR1, TLR7 | CYP11B1 1192/4885CYP11B2 1788/4885PRKCZ 874/4885 |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | CYP11B1 1317/4885CYP11B2 1289/4885PRKCZ 12/4885 |
| US-20080207608-A1 | 2-Propene-1-Ones As Hsp 70 Inducers | HSPB1, HSF1, HSPE1 | CYP11B1 475/4885CYP11B2 379/4885PRKCZ 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.